Startup Healthleap has raised $38 million across two funding rounds to expand an artificial intelligence platform that reads medical records and identifies patients who may have undiagnosed conditions or conditions not detected early. The funding includes an $8 million seed round co-led by Sequoia Capital and First Round Capital, and a $30 million Series A led by Hummingbird Ventures. The company did not disclose its valuation.
A Platform Combining Clinical Notes and Structured Data
Healthleap connects to a hospital’s electronic health record system, then analyzes data such as laboratory results, vital signs, weights, medications, nutrition orders and diagnoses, along with notes written by physicians and clinical teams. Its language models search those notes for indicators such as loss of appetite or weight, loss of muscle mass and difficulty swallowing, while distinguishing between a condition being mentioned and evidence that it is absent.
According to CEO and co-founder Josiah Meyer, the records of all hospitalized adult patients are analyzed every night. The following morning, a risk assessment is written into the care team’s usual workflow, with a dashboard displaying additional information about the patient’s medical trends.
The company emphasizes that the system does not diagnose patients; it draws the team’s attention to conditions that warrant closer review. The platform is currently used to monitor malnutrition and delirium, while other programs, including detection of aspiration pneumonia, pressure ulcers and the risk of readmission due to congestive heart failure, are undergoing further clinical validation.
From Three Hospitals to More Than 50
Healthleap says it expanded its partner base from three hospitals to more than 50 in one year. Its customers include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare. It also reported that its revenue grew more than tenfold over the same period, without disclosing the actual figures.
The company was founded in South Africa in 2022 by siblings Jemima Meyer and Josiah Meyer. It initially developed a clinical nutrition tool aimed at dietitians, then moved to a broader platform for detecting conditions that may not be identified early during a patient’s hospital stay.
What Changes in Practice?
The platform’s value lies in converting unstructured clinical notes, which may contain important signals that do not appear in traditional fields, into alerts that can be reviewed as part of the daily workflow. This is particularly important for malnutrition; research cited by the article indicates that the condition may affect between 20% and 50% of hospitalized patients and is associated with longer stays and complications such as infections and delayed wound healing.
At the University of Pennsylvania Hospital, Healthleap says its malnutrition program generated an annual financial impact of $23.8 million, including $6.3 million in additional reimbursements and $17.5 million from reducing length of stay. These figures are attributed by the company to its program and are not an independent assessment presented in the article.
Expansion and Limitations
Healthleap sells three-year contracts priced according to the number of licensed beds and also uses an outcome-based pricing model. The company says that all of its customers have so far achieved a direct financial return of at least five times the contract value, and in some cases more than 20 times annually. These are commercial claims whose verification methodology was not detailed in the source.
The company will direct the new funding toward engineering, product development, sales and customer success, with plans to add support for more than 40 major health conditions and later expand into outpatient and home care. Clinical validation across multiple cases, as well as measuring the accuracy of alerts and their actual effect on care decisions, remain important questions as the scope of use expands.